Brief: Xintela Completes Clinical Study With XSTEM In Difficult-To-Heal Leg Ulcers
13/02/2026 13:51
Feb 13 (Reuters) - Xintela AB XINT.ST: COMPLETES CLINICAL STUDY WITH XSTEM IN DIFFICULT-TO-HEAL LEG ULCERS PRIMARY GOAL TO INVESTIGATE SAFETY AND TOLERABILITY ACHIEVED Source text: ID:nMFN9ZdPwW Further company coverage: XINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects